Phase 2 study to investigate the efficacy and safety of ZK-epothilone (ZK-Epo; ZK 219477) [sagopilone] in patients with metastatic breast cancer

Trial Profile

Phase 2 study to investigate the efficacy and safety of ZK-epothilone (ZK-Epo; ZK 219477) [sagopilone] in patients with metastatic breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Berlex Inc
  • Most Recent Events

    • 12 Feb 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top